RAFT polymerisation technology enabling the biotech industry

Mirus Bio Vice President of Scientific Operations Scott Hayes said the agreement would allow the company to broaden its expertise.

“We expect that utilisation of RAFT will lead to new discoveries and expedite our product development efforts.”

Dr Scott Hayes, Vice President of Scientific Operations, Mirus Bio

“This agreement with CSIRO broadens the scope of specialised polymer design tools available to Mirus and facilitates our continued efforts to improve nucleic acid transfer capabilities. We expect that utilisation of RAFT will lead to new discoveries and expedite our product development efforts,” Dr Hayes said.

“CSIRO is very pleased to be working with Mirus Bio in the transfection space,” said Cathy Foley from CSIRO.

“The scientists at Mirus are leaders in introducing innovative products in this area and have developed a range of delivery technologies for researchers in the biotech industry that can make use of our polymer technology,” she said.

RAFT has very broad applicability in the biotech and biomedical industry because of the need for new and improved multifunctional polymers for many different applications. RAFT enables the rapid, rational design and prove-out of bespoke macromolecules,” Dr Foley said.

Contact CSIRO if you would like to discuss using RAFT for your industrial application.

Media resources

Click image for high resolution version

Mirus Bio will be using CSIRO’s RAFT technology in the biotech sector.